FDA Efficacy Recommendations Vary for Hypogonadotropic Hypogonadism Drugs
This article, written by Meg Egan Auderset at Clarivate Analytics, describes how the new draft industry guidance from the US…
Read more
Ensuring Launch Success in Rare Disease Areas by Creating a Value Story
A number of trends (both in science and on the regulatory front) bode well for the development and availability of…
Clinical Trials in Russia – Report on Q3 of 2017
The Russian MoH approved 158 new clinical trials of all types including local and bioequivalence studies during Q3 2017, demonstrating…
Combined Studies Under the New EU Clinical Trial Regulation
The key aim of the new EU Clinical Trial Regulation, which is currently planned for implementation in mid-2019, is to…
Paediatric Melanoma and the Pharmaceutical Industry
The age of paediatric melanoma used to be a theoretical discussion, but has become a real-life challenge due to arbitrary…
A Review of FDA’s Updated Guidance for Developing Drugs to Treat Early Alzheimer’s Disease
There has been a renewed interest in clinical trials of drugs to treat early Alzheimer’s disease, owing partially to recent…
Clinical Trials Down Under Australia and New Zealand – A Competitive Region
The Australian clinical trials landscape has developed considerably over recent years with over 1000 new clinical trials commencing each year…
Russian Clinical Trials Market in 2017
Following on from the last article featured by Svetlana Zavidova from the Association of Clinical Trials Organizations (ACTO) in the…
Developing Talent for the Future of Clinical Research
Clinical research is a rapidly evolving and dynamic environment and the sector is undergoing significant changes on a number of…
How to Rescue a Clinical Trial, if You Must
Conducting a clinical trial is a huge and complex undertaking, and there are, more often than not, challenges. And in…